We scan new podcasts and send you the top 5 insights daily.
Rob points out all three chemo-IO trials raised pathological complete response by roughly 8-10%, yet only Niagara improved survival. He says path CR is not clinically meaningful by itself and has never been proven as a surrogate for event-free or overall survival. So similar activity signals cannot explain divergent outcomes.
Unlike in breast or bladder cancer, the significant improvement in pathologic response in the PROTEUS trial did not translate to a similarly impressive benefit in metastasis-free survival. This disconnect suggests that eliminating tumor in the prostate specimen is not a reliable surrogate for long-term outcomes in this disease setting.
KEYNOTE-522 data shows that achieving pathologic complete response (path CR) with pembrolizumab offers a greater survival benefit than achieving path CR with chemotherapy alone. This suggests immunotherapy provides a lasting benefit beyond just initial tumor eradication.
Niagara's control arm had 60% two-year event-free survival versus about 70% in the negative trials. The discussion says this makes Niagara the highest-risk population, where more events and greater risk can let an immune-therapy benefit show up. That may explain more than drug differences alone.
In the Luminosity study of Taliso-V for MET-overexpressed NSCLC, patients with high C-MET expression had better response rates than those with intermediate expression. However, this did not translate into a significant improvement in median Progression-Free Survival (PFS) or Overall Survival (OS).
Data from trials like CheckMate 816 shows that achieving a Pathologic Complete Response (PCR) after neoadjuvant chemo-immunotherapy is a powerful early surrogate endpoint. Patients with PCR demonstrate markedly improved overall and event-free survival.
A pooled FDA analysis of four major kidney cancer trials found no "magic number" or threshold for tumor shrinkage that guarantees a favorable outcome. Instead, the relationship is linear: any incremental increase in tumor reduction correlates with better 36-month overall survival.
Unlike immunotherapy, neoadjuvant osimertinib yields poor pathologic complete response (pCR) rates. However, it significantly improves major pathologic response (MPR) and survival, suggesting pCR may be the wrong efficacy endpoint for cytostatic EGFR TKIs, which have a different mechanism of action than immunotherapy.
While depth of response strongly predicts survival for an individual patient, the FDA analysis concludes it cannot yet be used as a surrogate endpoint to replace overall survival in pivotal clinical trials. It serves as a measure of drug activity, similar to response rate, but is not sufficient for drug approval on its own.
The LEAP-010 trial showed a combination therapy improved tumor response and progression-free survival but failed to improve overall survival, the ultimate measure of benefit. This highlights the risk of relying on surrogate endpoints, which can be misleading, especially when a treatment adds significant toxicity.
Keynote 671 data shows patients without a pathologic complete response after neoadjuvant chemoimmunotherapy have a 5-year event-free survival of only 43%. This outcome is comparable to standard chemoradiation (the PACIFIC regimen), questioning the benefit of pushing for surgery in poor responders.